Capvaxvie is developed by University of Alabama at Birmingham.

What development phase is Capvaxvie in?

Capvaxvie is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Capvaxvie

University of Alabama at Birmingham · FDA-approved active Biologic Quality 0/100

Capvaxvie, developed by the University of Alabama at Birmingham, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Capvaxvie
Sponsor	University of Alabama at Birmingham
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results